Compare MATH & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATH | TIL |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.8M | 74.7M |
| IPO Year | N/A | 2021 |
| Metric | MATH | TIL |
|---|---|---|
| Price | $1.95 | $7.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 48.0K | ★ 262.8K |
| Earning Date | 03-06-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $44,567,257.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.95 | ★ N/A |
| Revenue Growth | ★ 165.86 | N/A |
| 52 Week Low | $1.25 | $5.67 |
| 52 Week High | $4.17 | $42.79 |
| Indicator | MATH | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 36.11 | 35.78 |
| Support Level | $1.90 | $6.79 |
| Resistance Level | $2.09 | $7.32 |
| Average True Range (ATR) | 0.13 | 0.27 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 9.62 | 69.10 |
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.